ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of TeleOphthalmology in AMD-TeleMedicine Solutions to Improve Patient Access and Quality of Vision Outcomes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01581606
Recruitment Status : Completed
First Posted : April 20, 2012
Last Update Posted : November 6, 2017
Sponsor:
Collaborators:
The Physicians' Services Incorporated Foundation
Academic Health Science Centres
Information provided by (Responsible Party):
Lawson Health Research Institute

Brief Summary:

Hypothesis:

The use of teleophthalmology for patient screening will result in more rapid patient access for treatment. The use of teleophthalmology to monitor patients with wet AMD post-treatment will result in maintenance of good visual outcomes combined with a reduction in patient travel and improved patients satisfaction in a cost effective manner.

Objectives :

The Evaluation of Teleophthalmology in AMD project objectives are as follows:

  1. To evaluate the efficacy of teleophthalmology in screening patients referred to retina specialists for suspected wet AMD.
  2. To compare the "time to treatment/retreatment" with this program with that of patient's entering the system and being followed conventionally to determine the efficacy of teleophthalmology to provide rapid entry/re-entry into treatment programs.
  3. To determine the efficacy of teleophthalmology in monitoring patients with wet AMD post therapy.
  4. To determine the compliance rate for monitoring wet AMD during follow-up utilizing teleophthalmology.
  5. To evaluate the cost effectiveness of teleophthalmology in screening/monitoring wet AMD patients including direct costs to the OHIP system and indirect costs to the patient/caregiver.
  6. To assess patient satisfaction with teleophthalmology versus standard clinical care in the monitoring of post-treatment wet AMD.
  7. To evaluate teleophthalmology as a tool for communication between community based Optometrists /Ophthalmologists and Retina Specialists.

Condition or disease
Age Related Macular Degeneration

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 169 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Evaluation of TeleOphthalmology in Age-related Macular Degeneration (AMD) - TeleMedicine Solutions to Improve Patient Access and Quality of Vision Outcomes.
Actual Study Start Date : April 30, 2013
Actual Primary Completion Date : April 4, 2014
Actual Study Completion Date : April 7, 2014

Resource links provided by the National Library of Medicine


Group/Cohort
Group 1R and 1T AMD Screening
Group 1 patients will be collected through all referrals to any of the physician investigators with a provisional diagnosis of possible wet AMD. Any request for clinical evaluation of a patient for presumed wet AMD will be randomized into Group 1R (Routine Screening) and Group 1T (Tele-ophthalmology screening).
Group 2R and 2T Follow up
Group 2 patients will be collected from the patients previously treated for wet AMD within the practices of the physician investigators. All patients in whom the disease is inactive (not receiving active treatment) and who therefore require monitoring will be randomized into Group 2R (Routine Monitoring) and Group 2T (Teleophthalmology Monitoring).



Primary Outcome Measures :
  1. Wait time for treatment (naive versus follow-up patients). [ Time Frame: One month for Tele-screening evaluation in both groups. ]

Secondary Outcome Measures :
  1. Patient satisfaction. [ Time Frame: One month. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Group 1: Patients will be collected from all referrals with a provisional diagnosis of possible Wet-AMD to any of the physician investigators.

Group 2: Subjects will be collected from patients previously treated at this institution for wet-AMD within the practices of the physician investigators.

Criteria

Inclusion Criteria:

  • Group 1: Patients will be collected from all referrals with a provisional diagnosis of possible Wet-AMD to any of the physician investigators. These patients will subsequently be randomized into Group 1R (Routine Screening) and Group 1T (Tele-ophthalmology Screening)
  • Group 2: Patients will be collected from patients previously treated at this institution for Wet-AMD within the practices of the physician investigators. All patients in whom the disease is inactive (not receiving active treatment) and who require monitoring will be randomized into Group 2R (Routine Monitoring) and Group 2T (Tele-Ophthalmology Monitoring).

Exclusion Criteria:

  • Patients will be excluded if they live more than an hours driving distance from London or from one of the afore-mentioned Ocular Health Centre(s)
  • Patients with a presumed diagnosis of Wet-AMD at the time of referral who have previously had diagnostic imaging performed as part of the referral will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01581606


Locations
Canada, Ontario
Ivey Eye Institute, St. Joseph's Health Care
London, Ontario, Canada, N6A 4V2
Sponsors and Collaborators
Lawson Health Research Institute
The Physicians' Services Incorporated Foundation
Academic Health Science Centres
Investigators
Principal Investigator: Thomas G Sheidow, MD, FRCSC Ivey Eye Institute, St. Joseph's Health Care, London, Ontario, Canada

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT01581606     History of Changes
Other Study ID Numbers: 18045E
First Posted: April 20, 2012    Key Record Dates
Last Update Posted: November 6, 2017
Last Verified: November 2017

Keywords provided by Lawson Health Research Institute:
Age Related Macular Degeneration
Teleophthalmology
Screening
Diagnosis
Timing
Treatment

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases